New Study Shows Path to ‘Dial Down’ Autoimmunity without Compromising Immune Response

Source: Scripps Research Institute

A new study led by scientists at The Scripps Research Institute (TSRI) shows how dangerous autoimmune responses, seen in diseases such as lupus and multiple sclerosis, might be “dialed down” without compromising the immune system’s ability to fight viruses and bacteria.
 
Published in the journal Proceedings of the National Academy of Sciences, the study defines an unexpected mechanism at work in an anti-autoimmune drug candidate called ozanimod (now under development by Celgene)...

For human patients, the researchers see a potential advantage in using agonists such as ozanimod to limit immune tissue damage while preserving a patient’s ability to protect against opportunistic infections.